Member Posts > Cardiol Therapeutics: CRDL Upgraded to 'Strong Buy'!
Rodman & Renshaw boosts Cardiol Therapeutics (NASDAQ: CRDL) on confidence in CardiolRx, a promising Phase II heart disease treatment.
📊 Stock Snapshot:
✅ Price: $1.22 | Target: $8.40
✅ Debt-Free, Strong Liquidity
🔥 Institutional interest growing-Biotech breakout ahead?

#CardiolTherapeutics #CRDL #BiotechStocks #StrongBuy #StockMarket #PharmaInvesting #HealthcareInnovation #CardiolRx #HeartDisease #ClinicalTrials #InvestorAlert #NASDAQ #BiotechInvesting #StockAnalysis #MedicalBreakthroughs